fmp1
Vaccineexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2001 (NCT01556945)
Timeline
Indications
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- fmp1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00223990 | Phase 2 | Mar 1, 2005 | GlaxoSmithKline, Kenya Medical Research Institute, PATH, United States Agency for International Development, United States Army |
| NCT00308061 | Phase 1 | Jul 1, 2003 | GlaxoSmithKline, National Institute of Allergy and Infectious Diseases (NIAID), United States Agency for International Development, United States Army, University of Bamako |
| NCT01556945 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2001 | GlaxoSmithKline, United States Army |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 0 | 2 | 2001 |
| United States Army | Government | 3 | 3 | 2 | 2001 |
| United States Agency for International Development | Government | 2 | 0 | 2 | 2003 |
| Kenya Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2005 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2003 |
| PATH | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Bamako | Academic/Hospital | 1 | 0 | 1 | 2003 |
7 organizations
Page 1 / 1